Neurocrine, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on the stock and has a $180.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mohit Bansal has given his Buy rating due to a combination of factors that highlight Neurocrine’s promising growth trajectory. The significant increase in patient enrollment for Crenessity, coupled with improved reimbursement coverage, indicates a robust launch and suggests strong commercial execution by the company. This performance is expected to instill confidence among investors regarding Neurocrine’s future growth prospects.
Despite a slight reduction in the midpoint guidance for Ingrezza, the overall sales performance reflects positive impacts from expanded access and increased demand. Although there was a minor decline in Ingrezza’s market share compared to Austedo, the results are still favorable, especially considering Teva’s raised guidance for Austedo. These elements collectively support the Buy rating, as they demonstrate Neurocrine’s ability to navigate challenges and capitalize on growth opportunities.
NBIX’s price has also changed moderately for the past six months – from $153.290 to $136.760, which is a -10.78% drop .